MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- NATCO PHARMA - TEVA PHARMA (Israel)
NATCO PHARMA vs TEVA PHARMA (Israel) - Comparison Results
TEVA PHARMA (Israel)
Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
Financials
 NATCO PHARMA  TEVA PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| NATCO PHARMA Mar-19 |
TEVA PHARMA Dec-13 |
NATCO PHARMA/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 849 | 3,043 | - | |
| Low | Rs | 557 | 2,643 | - | |
| Sales per share (Unadj.) | Rs | 573.8 | 1,746.3 | - | |
| Earnings per share (Unadj.) | Rs | 176.0 | 109.1 | - | |
| Cash flow per share (Unadj.) | Rs | 198.2 | 250.2 | - | |
| Dividends per share (Unadj.) | Rs | 6.25 | 95.50 | - | |
| Dividend yield (eoy) | % | 0.9 | 3.4 | 26.5% | |
| Book value per share (Unadj.) | Rs | 842.7 | 1,939.8 | - | |
| Shares outstanding (eoy) | m | 36.50 | 848.00 | - | |
| Bonus/Rights/Conversions | BB | - | - | ||
| Price / Sales ratio | x | 1.2 | 1.6 | 75.2% | |
| Avg P/E ratio | x | 4.0 | 26.1 | 15.3% | |
| P/CF ratio (eoy) | x | 3.5 | 11.4 | 31.2% | |
| Price / Book Value ratio | x | 0.8 | 1.5 | 56.9% | |
| Dividend payout | % | 3.6 | 87.5 | 4.1% | |
| Avg Mkt Cap | Rs m | 25,660 | 2,410,949 | 1.1% | |
| No. of employees | `000 | 5.0 | 44.9 | 11.0% | |
| Total wages/salary | Rs m | 3,559 | 0 | - | |
| Avg. sales/employee | Rs Th | 4,225.3 | 32,949.0 | 12.8% | |
| Avg. wages/employee | Rs Th | 718.0 | 0 | - | |
| Avg. net profit/employee | Rs Th | 1,295.9 | 2,058.3 | 63.0% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 20,945 | 1,480,891 | 1.4% | |
| Other income | Rs m | 1,302 | 0 | - | |
| Total revenues | Rs m | 22,247 | 1,480,891 | 1.5% | |
| Gross profit | Rs m | 7,948 | 405,543 | 2.0% | |
| Depreciation | Rs m | 810 | 119,702 | 0.7% | |
| Interest | Rs m | 193 | 29,087 | 0.7% | |
| Profit before tax | Rs m | 8,247 | 256,754 | 3.2% | |
| Minority Interest | Rs m | 0 | 1,166 | 0.0% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | -168,545 | 0.0% | |
| Tax | Rs m | 1,823 | -3,135 | -58.2% | |
| Profit after tax | Rs m | 6,424 | 92,510 | 6.9% | |
| Gross profit margin | % | 37.9 | 27.4 | 138.6% | |
| Effective tax rate | % | 22.1 | -1.2 | -1,810.6% | |
| Net profit margin | % | 30.7 | 6.2 | 491.0% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 23,472 | 1,000,188 | 2.3% | |
| Current liabilities | Rs m | 7,287 | 872,249 | 0.8% | |
| Net working cap to sales | % | 77.3 | 8.6 | 894.4% | |
| Current ratio | x | 3.2 | 1.1 | 280.9% | |
| Inventory Days | Days | 92 | 91 | 101.5% | |
| Debtors Days | Days | 88 | 96 | 92.0% | |
| Net fixed assets | Rs m | 18,648 | 483,692 | 3.9% | |
| Share capital | Rs m | 365 | 3,645 | 10.0% | |
| Net worth | Rs m | 30,760 | 1,644,989 | 1.9% | |
| Long term debt | Rs m | 0 | 757,212 | 0.0% | |
| Total assets | Rs m | 43,031 | 3,384,310 | 1.3% | |
| Interest coverage | x | 43.7 | 9.8 | 445.0% | |
| Debt to equity ratio | x | 0 | 0.5 | 0.0% | |
| Sales to assets ratio | x | 0.5 | 0.4 | 111.2% | |
| Return on assets | % | 15.4 | 3.6 | 428.0% | |
| Return on equity | % | 20.9 | 5.6 | 371.4% | |
| Return on capital | % | 27.4 | 4.9 | 556.4% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 6,688 | 235,977 | 2.8% | |
| From Investments | Rs m | -6,122 | -83,616 | 7.3% | |
| From Financial Activity | Rs m | -509 | -283,071 | 0.2% | |
| Net Cashflow | Rs m | 66 | -130,710 | -0.1% | |
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 72.9 Rs / USD
Compare NATCO PHARMA With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US)
Compare NATCO PHARMA With: SHASUN PHARMA PIRAMAL ENTERPRISES GLENMARK PHARMA PANACEA BIOTECH TTK HEALTHCARE
Today's Market
A Time Correction in the Nifty(Momentum Moves)
The week belonged to the bulls after bears ended the party in February. March started with gains for the bulls but historically, March has been a bears' month.
Related Views On News
NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)
Feb 17, 2020 | Updated on Feb 17, 2020For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)
Aug 13, 2019 | Updated on Aug 13, 2019For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
More Views on NewsMost Popular
It's the Beginning of a New Bull Phase in Smallcaps (Profit Hunter)
Feb 24, 2021Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
Make Rs 5,000 Per Day Trading the Market (Fast Profits Daily)
Feb 25, 2021In this video, I'll show you how to get started on the path to daily trading profits.
The Hidden Tesla in My Great Indian Wealth Project (Profit Hunter)
Feb 23, 2021An Indian company founded three decades ago in a garage caught my attention...
Gold 65,000 and Silver 84,000 in 2022
Feb 26, 2021In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.
More
